Clarius Group LLC Has $1.10 Million Position in Boston Scientific Corporation $BSX

Clarius Group LLC lowered its position in shares of Boston Scientific Corporation (NYSE:BSX) by 10.7% in the second quarter, Holdings Channel reports. The firm owned 10,267 shares of the medical equipment provider’s stock after selling 1,226 shares during the period. Clarius Group LLC’s holdings in Boston Scientific were worth $1,103,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. 1248 Management LLC acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $27,000. Sound Income Strategies LLC boosted its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $37,000. Finally, Activest Wealth Management boosted its holdings in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 373 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $97.30 on Friday. The company’s fifty day simple moving average is $102.93 and its 200-day simple moving average is $102.06. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $144.17 billion, a PE ratio of 57.91, a P/E/G ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the firm posted $0.62 earnings per share. The company’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BSX shares. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Truist Financial upped their price target on shares of Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a report on Wednesday. Raymond James Financial upped their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday. Finally, Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $120.79.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.